Skip to content

Buying a Pharmacy

Accountants for pharmacy buyers: due diligence, deal structure, and the tax decisions no broker will make for you.

When you buy a community pharmacy, what you're paying for is its NHS contract, and market entry is regulated under the NHS (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013. The broker finds the deal; we do the work the broker can't: financial due diligence on the contract income, the share-versus-asset structuring decision, goodwill tax treatment, and a set of accounts your lender will actually accept. Whether you are an existing owner adding a second store or a first-time buyer, the NHS-contract layer is where the surprises sit, and we work through it with you remotely, wherever in England the pharmacy is.

0.5% vs up to 5%
Stamp duty on a share purchase (0.5% on share value, until the announced Securities Transfer Tax replaces it from late 2027) against SDLT at non-residential rates up to 5% on property in an asset purchase: the structuring decision is a real-money choice
£1,000,000
Annual Investment Allowance available at 100% on qualifying pharmacy fit-out plant and machinery, including dispensary robots, refrigeration, and shelving; a company buying new main-rate plant can take full expensing at 100% instead
40% FYA
First-year allowance on new main-rate plant bought from 1 January 2026 (CAA 2001 s45U, inserted by FA 2026), open to any business, though a company normally takes full expensing instead; the main-rate writing-down allowance is 14% (down from 18%). Announced at Budget 2026, not yet law: 50% FYA from 1 January 2027, and a 12% WDA for periods starting on or after 1 April 2027 (companies) or 6 April 2027 (income tax)

What makes accounting for pharmacy buyers different.

The NHS contract is the asset, not the shop

Opening, relocating, or acquiring a pharmacy engages the NHS (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013. The NHS contract, the prescription volume it supports, and the NHSBSA payment history are what you are buying. GPhC-registered premises and the superintendent pharmacist requirements for company owners are the regulatory mechanics we cover on the ownership side. The financial due diligence must validate the contract, not just the till.

Share purchase or asset purchase: a structuring decision with tax consequences

An asset purchase attracts SDLT on any property at non-residential and mixed-use rates, which rise to 5% at the higher bands, and a new lease pays SDLT on its rent too. A share purchase attracts 0.5% stamp duty on the shares (until the announced Securities Transfer Tax replaces it from late 2027) but means you inherit the selling company's full history, including any historic tax exposures, pending HMRC enquiries, and employment liabilities. On an asset purchase, VAT stays off the price only if the deal is a transfer of a going concern, and every condition in VAT Notice 700/9 has to hold: the assets come with the business; you carry on the same kind of business; you're VAT registered, or become so through the transfer; any part you buy can run on its own; the sale isn't one in a chain of immediately consecutive transfers; trading doesn't significantly break; and if the premises would be standard-rated (because the seller opted to tax, or the freehold is of a building less than 3 years old), you must have opted to tax yourself, told HMRC by the relevant date, and confirmed to the seller that your option isn't disapplied. The right structure depends on the target's history, the property position, and your own tax position. We model both before you make an offer.

Goodwill dominates pharmacy pricing but CT relief is restricted

Pharmacy prices are driven by the NHS contract and item volume, and goodwill dominates the purchase price. So the goodwill cost when you buy a pharmacy is what's left of the price after the stock, fixtures and equipment are valued, and it goes on your balance sheet as an intangible asset. On a company purchase, corporation tax relief on goodwill is restricted and available only in limited cases at fixed rates: 6.5% a year, and then only if the company buys qualifying IP assets along with the business, capped at goodwill of six times the IP's cost. That affects your real cost of acquisition and must be factored into affordability. Valuation stays method-level (adjusted EBITDA and pence-per-item approaches are the standard methods), and we never assert a specific multiple. See our pharmacy valuation and goodwill service for the full picture.

Lender-ready accounts require NHS-adjusted maintainable earnings

A lender financing a pharmacy acquisition needs to see maintainable earnings with Category M margin normalised (DHSC resets those prices each quarter) and any one-off items in the historic accounts taken out, plus a working-capital line for the FP34 timetable: the first advance, 100% of NHSBSA's estimate, comes around the 10th of the month after dispensing and the balance about two months after submission, so you pay for the first month's stock and wages before it lands. Statutory accounts don't set those adjustments out. We prepare the financial analysis your lender needs and link it to the purchase affordability calculator for scenario modelling.

How we help pharmacy buyers.

Financial due diligence on the contract and the accounts

We verify FP34 income against NHSBSA payment statements, test Category M margin exposure, check the VAT retail-scheme position, and review payroll and staff costs for TUPE-relevant liabilities. This is the due-diligence layer the broker does not provide. See our pharmacy purchase accounting service for the full scope and use our FP34 cash-flow estimator to see when the advance and the reconciliation land for a month of the target's dispensing.

Share vs asset structure and goodwill treatment

We model the stamp-duty and SDLT cost of both structures, assess the CT relief position on goodwill for an asset purchase, and identify any history in the target company that makes shares more or less attractive. The output is a clear comparison you can put in front of your solicitor and your lender before heads of terms are agreed.

Capital allowances on the fit-out and ongoing accounting setup

Pharmacy fit-outs (shelving, dispensary robots, refrigeration, security systems) qualify as plant and machinery, and so does a safe: the Capital Allowances Act names safes among the items its building rules don't exclude (CAA 2001 s23, List C). In your accounts a safe is equipment, a fixed asset you depreciate; for tax, the relief depends on how you trade. A company buying new main-rate plant normally takes full expensing (100% in the year it's bought), and a 50% first-year allowance on new special-rate plant. A sole trader or partnership claims the Annual Investment Allowance (100% on up to £1,000,000 of qualifying expenditure in the year of spend), then the 40% first-year allowance on new main-rate plant bought from 1 January 2026 (CAA 2001 s45U), with the rest in the 14% main pool or the 6% special-rate pool; on the cash basis, you simply deduct equipment when you pay for it. Full expensing and the 40% allowance need plant that's new and unused, so equipment you take over with the business can't get them, but the AIA, which companies can claim too, can cover it. For expenditure from 1 January 2027 the main rate first-year allowance is due to rise from 40% to 50%, and the main rate writing-down allowance is due to fall from 14% to 12% for chargeable periods beginning on or after 1 April 2027 (companies) or 6 April 2027 (income tax), with a hybrid rate for a period spanning the date (announced at Budget 2026 on 28 October 2026, still to pass in the Finance Bill). Qualifying works to the building itself attract the Structures and Buildings Allowance at 3% straight line. We claim the right allowances from day one of ownership, then run the monthly accounts, VAT and payroll from completion on.

Common questions

Effectively the NHS contract. The contract, the prescription volume it supports, and the NHSBSA payment stream are what give the business its value. Market entry and ownership changes engage the NHS (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013. The financial due diligence must validate contract income, not just the retail till.

An asset purchase attracts SDLT on property at non-residential rates up to 5%. A share purchase attracts 0.5% stamp duty on the shares (until the announced Securities Transfer Tax replaces it from late 2027) but means you inherit the selling company's history. The right answer depends on the property position, the target company's historic tax exposure, and how goodwill CT relief plays out in each structure. We model both before you commit.

Pharmacy goodwill is driven by the NHS contract and item volume. It dominates the purchase price because the contract itself is what generates the income stream. On a company acquisition, CT relief on purchased goodwill is restricted and only available in limited cases. That restricted relief position affects the real after-tax cost of the deal and must be assessed deal-by-deal.

At minimum: FP34 NHSBSA payment history versus recorded income, Category M margin exposure (how margin has moved as DHSC resets prices each quarter), VAT retail-scheme correctness, staff contracts and TUPE position, GPhC registration status, and any outstanding HMRC enquiries or historic tax exposures in the company. We provide pharmacy-specific financial due diligence that covers all of these.

Yes. Dispensary equipment, robots, refrigeration, shelving, and security systems are plant and machinery. A company buying them new normally takes full expensing, 100% in the year of spend (50% first-year allowance on special-rate items). The Annual Investment Allowance covers up to £1,000,000 at 100% in the year of spend for any business, second-hand equipment bought with the pharmacy included. Above it, the 40% first-year allowance on new main-rate plant bought from 1 January 2026 is open to any business, though a company normally takes full expensing instead, and the main-rate writing-down allowance is now 14% (down from 18%). On the cash basis, a sole trader or partnership deducts equipment as an expense instead. For expenditure from 1 January 2027 the main rate first-year allowance is due to rise from 40% to 50%, and the main rate writing-down allowance is due to fall from 14% to 12% for chargeable periods beginning on or after 1 April 2027 (companies) or 6 April 2027 (income tax), with a hybrid rate for a period spanning the date (announced at Budget 2026 on 28 October 2026, still to pass in the Finance Bill). Works to the building structure itself qualify for the Structures and Buildings Allowance at 3% straight line.

Yes. The financial profile changes substantially: you move from Self Assessment on day-rate income to managing NHS contract cash flow, FP34 reconciliation, VAT retail schemes, and an employer payroll. Our locum pharmacists page covers your current tax position, and we can walk you through what owning the contract changes.

Speak to a pharmacy finance specialist.

Tell us about the pharmacy you're buying and we will reply within 24 hours.

Step 1 of 2 · About you

Optional: a bit more detail (helps us prepare)